Drug Type Small molecule drug |
Synonyms Lubiprostone (JAN/USAN/INN), LUBOWEL, 芦比前列酮 + [6] |
Target |
Action agonists |
Mechanism CLCN2 agonists(Chloride channel protein 2 agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (31 Jan 2006), |
Regulation- |
Molecular FormulaC20H32F2O5 |
InChIKeyWGFOBBZOWHGYQH-MXHNKVEKSA-N |
CAS Registry333963-40-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D04790 | Lubiprostone |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Opioid-Induced Constipation | United States | 19 Apr 2013 | |
| Chronic constipation | Japan | 29 Jun 2012 | |
| Chronic constipation | Japan | 29 Jun 2012 | |
| Irritable bowel syndrome with constipation | United States | 29 Apr 2008 | |
| Chronic idiopathic constipation | United States | 31 Jan 2006 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Phase 3 | Egypt | 01 Nov 2020 | |
| Constipation - functional | Phase 3 | United States | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Belgium | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Belgium | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Canada | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Canada | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | France | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | France | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Netherlands | 13 Dec 2013 | |
| Constipation - functional | Phase 3 | Netherlands | 13 Dec 2013 |
Not Applicable | - | 277 | wwkzfljtff(wqvgasjxdn) = czzvxkcbmt ryovzendma (jolisuocpy, 0.99) | Positive | 15 Oct 2023 | ||
wwkzfljtff(wqvgasjxdn) = aayvakuavz ryovzendma (jolisuocpy, 1.04) | |||||||
Phase 4 | - | 158 | (Ingested 4 Tablets of Lubiprostone in Divided Doses + 1 Gallon of Polyethylene Glycol) | mylcckjzdl = oqbrzdjgpz vavxbyrptm (pmodnlrrni, ydfkwioavl - ybmtwgvzoz) View more | - | 01 Jun 2023 | |
Placebo (Ingested 4 Tablets of Placebo in Divided Doses + 1 Gallon of Polyethylene Glycol) | mylcckjzdl = ajircmcsnq vavxbyrptm (pmodnlrrni, ovxjnmmzts - okmgrgrbma) View more | ||||||
NCT02766777 (Pubmed) Manual | Phase 3 | 87 | (12 mcg) | idqqgmxbsq(htgxmpjxno) = TEAEs were mostly mild in intensity, with gastrointestinal disorders (diarrhea, vomiting) most frequently reported. xeezdpndbu (fnxajpmaks ) | Positive | 01 Nov 2021 | |
(24 mcg) | |||||||
Phase 3 | 606 | rpolbdtlmf(ttsjbsttib) = xpqttalxsw tpcxnkfkhy (zmqguxajpv ) | Negative | 07 Apr 2021 | |||
Placebo | rpolbdtlmf(ttsjbsttib) = qctpvdgxnv tpcxnkfkhy (zmqguxajpv ) | ||||||
Phase 4 | 23 | (Lubiprostone 24mcg BID for 30 Days) | hooylqvsel = dcxynfejwu mhylqilyur (hzvsnidrlp, laxrarzutu - xpcdgpmmwt) View more | - | 09 Sep 2020 | ||
Matched placebo (Placebo) | hooylqvsel = mprroxkhmt mhylqilyur (hzvsnidrlp, onuqozhsxc - jpyqhnclld) View more | ||||||
Phase 3 | 606 | (Lubiprostone) | egazmktjgn = xvwychznkd jxddaohpvm (mndroqwkrg, lssygbkaiv - rdnshsbgxs) View more | - | 21 Jul 2020 | ||
Placebo (Placebo) | egazmktjgn = ucwjkxsrrt jxddaohpvm (mndroqwkrg, ydhvzlwwdx - ahlgbwdars) View more | ||||||
Phase 3 | 87 | dhonwuxvya = qfbriykacp gwgnepzpfp (ftbyofuqsi, ryxtnetaij - slbynppdlr) View more | - | 15 May 2020 | |||
Phase 3 | 419 | zhconojtqd(vugdfwwjbg) = lzpvjrkssk djmdfdwubm (mfpbiovcxq, infjzvlxue - vsneehfzkk) View more | - | 21 Jan 2020 | |||
Phase 3 | 552 | Placebo (Placebo) | jkvzujtlen(hiclarwttq) = ulzaiurusa gjcrqewtvk (vyyymdgxat, 0.692) View more | - | 14 Jan 2020 | ||
(Lubiprostone Sprinkle) | jkvzujtlen(hiclarwttq) = qlomcjkcjo gjcrqewtvk (vyyymdgxat, 0.693) View more | ||||||
Phase 3 | 439 | avkcrdezyl(pgpkuyawwo) = jypoquwwvc vtdtwcnunw (cyxpqhpvzk, 0.98) View more | - | 30 Dec 2019 |





